EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) reported a net loss of $67.6 million, or $(0.81) per share, for the quarter ended December 31 2025. The company’s total net revenue for the quarter was $0.6 million, a steep decline from $11.6 million in the same period a year earlier, driven largely by the termination of the ANI commercial supply agreement and the recognition of remaining deferred revenue from the 2023 YUTIQ® license agreement.
Operating expenses rose to $71.0 million from $56.8 million a year earlier, reflecting the continued investment in Phase 3 trials for the company’s lead candidate DURAVYU in wet age‑related macular degeneration and diabetic macular edema. The increase is largely attributable to higher research and development costs associated with the pivotal studies, while selling, general and administrative expenses grew modestly.
The company’s consensus earnings estimate was $-0.78 per share, so the actual result of $(0.81) represents a miss of $-0.03, or 3.9 %. Revenue was also below consensus, which ranged from $0.54 million to $1.03 million; the $0.6 million reported is a miss of roughly $0.04 to $0.43 million. The revenue shortfall is largely a result of the loss of legacy product sales and the end of deferred revenue recognition, rather than a decline in demand for the company’s pipeline products.
Cash, cash equivalents and marketable securities stood at $306 million as of December 31 2025, giving the company a runway into the fourth quarter of 2027. Management emphasized that the strong cash position will support the ongoing Phase 3 studies and the eventual regulatory submission of DURAVYU. "Following a year of exceptional execution across our pivotal DURAVYU programs, EyePoint enters 2026 from a position of strength as we prepare to deliver on key Phase 3 milestones and showcase the potential of DURAVYU's best‑in‑class safety and efficacy profile," said President and CEO Jay S. Duker.
The market reacted to the results with a modest pre‑market decline of 1.26 % and a close‑market drop of 0.11 %. Investors focused on the revenue miss and the higher-than‑expected operating‑expense growth, while the company’s cash runway and the anticipated mid‑2026 data readout for DURAVYU in wet AMD were viewed as mitigating factors.
Overall, the earnings release highlights the company’s continued financial pressure from high R&D spending and declining legacy revenue, but also underscores the strategic focus on the single‑asset pipeline and the substantial cash cushion that will allow EyePoint to pursue the critical Phase 3 milestones for DURAVYU.
revised_sentiment_rating:-2}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.